Spots Global Cancer Trial Database for recurrent nasopharyngeal carcinoma
Every month we try and update this database with for recurrent nasopharyngeal carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC. | NCT03210389 | Recurrent Nasop... | Lobaplatin | 18 Years - 70 Years | Sun Yat-sen University | |
| Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma | NCT04376866 | Recurrent Nasop... | Toripalimab | 18 Years - 65 Years | Cancer Hospital of Guangxi Medical University | |
| Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma | NCT04921995 | Recurrent Nasop... Unresectable Na... Chemotherapy Ef... Immunotherapy Stereotactic Bo... | Tislelizumab | 15 Years - 90 Years | Fudan University | |
| A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma | NCT04627961 | Metastatic Naso... Recurrent Nasop... | TAS-102 | 21 Years - 99 Years | National University Hospital, Singapore | |
| Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma | NCT03930498 | Recurrent Nasop... | PD-1 blocking a... Chemotherapy IMRT | 18 Years - 65 Years | Sun Yat-sen University | |
| Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT | NCT04215510 | Recurrent Nasop... | endonasal endos... radiation thera... | 18 Years - 70 Years | Eye & ENT Hospital of Fudan University | |
| A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma | NCT04627961 | Metastatic Naso... Recurrent Nasop... | TAS-102 | 21 Years - 99 Years | National University Hospital, Singapore | |
| Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma | NCT05011227 | Recurrent Nasop... | Camrelizumab Chemotherapy endoscopic surg... | 18 Years - | Eye & ENT Hospital of Fudan University | |
| Nimotuzumab for Recurrent Nasopharyngeal Carcinoma | NCT03666221 | Recurrent Nasop... | Nimotuzumab | 18 Years - 70 Years | Fujian Cancer Hospital | |
| Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT | NCT04215510 | Recurrent Nasop... | endonasal endos... radiation thera... | 18 Years - 70 Years | Eye & ENT Hospital of Fudan University | |
| Adjuvant vs Surgery Only in Early-stage Recurrent NPC | NCT06228079 | Recurrent Nasop... | Immunotherapy,T... Chemotherapy,Ge... | 18 Years - 70 Years | Eye & ENT Hospital of Fudan University | |
| Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | NCT06029270 | Metastatic Naso... Recurrent Nasop... Stage IV Nasoph... | Biospecimen Col... Bone Scan Carboplatin Cisplatin Computed Tomogr... Gemcitabine Magnetic Resona... Nivolumab Positron Emissi... Relatlimab | 18 Years - | National Cancer Institute (NCI) | |
| Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma | NCT05011227 | Recurrent Nasop... | Camrelizumab Chemotherapy endoscopic surg... | 18 Years - | Eye & ENT Hospital of Fudan University | |
| Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | NCT06029270 | Metastatic Naso... Recurrent Nasop... Stage IV Nasoph... | Biospecimen Col... Bone Scan Carboplatin Cisplatin Computed Tomogr... Gemcitabine Magnetic Resona... Nivolumab Positron Emissi... Relatlimab | 18 Years - | National Cancer Institute (NCI) | |
| Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer | NCT04231864 | Epstein-Barr Vi... Metastatic Naso... Recurrent Nasop... Stage III Nasop... Stage IV Nasoph... Stage IVA Nasop... Stage IVB Nasop... | Durvalumab Epacadostat | 18 Years - | University of California, San Francisco | |
| PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients | NCT03907826 | Recurrent Nasop... | PD-1 blocking a... GP IMRT | 18 Years - 70 Years | Sun Yat-sen University | |
| Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. | NCT04405622 | Nasopharyngeal ... Recurrent Nasop... Metastatic Naso... Chemotherapy Ef... Immunotherapy | Toripalimab plu... | 18 Years - 70 Years | Sun Yat-sen University | |
| Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer | NCT04458909 | Metastatic Naso... Metastatic Naso... Metastatic Naso... Metastatic Naso... Nasopharyngeal ... Recurrent Nasop... Recurrent Nasop... Recurrent Nasop... Stage IV Nasoph... Stage IVA Nasop... Stage IVB Nasop... | Carboplatin Cisplatin Gemcitabine Nivolumab Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma | NCT03930498 | Recurrent Nasop... | PD-1 blocking a... Chemotherapy IMRT | 18 Years - 65 Years | Sun Yat-sen University | |
| Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. | NCT04405622 | Nasopharyngeal ... Recurrent Nasop... Metastatic Naso... Chemotherapy Ef... Immunotherapy | Toripalimab plu... | 18 Years - 70 Years | Sun Yat-sen University | |
| Nimotuzumab for Recurrent Nasopharyngeal Carcinoma | NCT03666221 | Recurrent Nasop... | Nimotuzumab | 18 Years - 70 Years | Fujian Cancer Hospital | |
| Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC | NCT06235203 | Recurrent Nasop... | endoscopic surg... Neoadjuvant the... Adjuvant therap... Adjuvant therap... | 18 Years - 70 Years | Eye & ENT Hospital of Fudan University | |
| MK-2206 in Recurrent Nasopharyngeal Carcinoma | NCT01370070 | Recurrent Nasop... | MK-2206 | 18 Years - | Chinese University of Hong Kong | |
| Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma | NCT04921995 | Recurrent Nasop... Unresectable Na... Chemotherapy Ef... Immunotherapy Stereotactic Bo... | Tislelizumab | 15 Years - 90 Years | Fudan University | |
| A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC. | NCT03210389 | Recurrent Nasop... | Lobaplatin | 18 Years - 70 Years | Sun Yat-sen University | |
| Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma | NCT05092217 | Nasopharyngeal ... | Tirelizumab salvage surgery | 18 Years - 70 Years | Eye & ENT Hospital of Fudan University | |
| Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma | NCT04425265 | Surgery Recurrent Nasop... | Plasma radiofre... Electrocautery ... | 18 Years - 70 Years | Sun Yat-sen University | |
| Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer | NCT04231864 | Epstein-Barr Vi... Metastatic Naso... Recurrent Nasop... Stage III Nasop... Stage IV Nasoph... Stage IVA Nasop... Stage IVB Nasop... | Durvalumab Epacadostat | 18 Years - | University of California, San Francisco | |
| Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure | NCT04586088 | Nasopharyngeal ... Recurrent Nasop... Metastatic Naso... Chemotherapy Ef... Immunotherapy Molecular Targe... | Apatinib plus C... | 18 Years - 70 Years | Sun Yat-sen University | |
| Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. | NCT04405622 | Nasopharyngeal ... Recurrent Nasop... Metastatic Naso... Chemotherapy Ef... Immunotherapy | Toripalimab plu... | 18 Years - 70 Years | Sun Yat-sen University | |
| Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC | NCT05350891 | Recurrent Nasop... | endoscopic surg... | 18 Years - | Eye & ENT Hospital of Fudan University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
